



SanBio publishes two-year, phase 1/2a clinical trial outcomes of patients with chronic ischemic stroke after implantation of SB623 stem cells in the peer-reviewed Journal of Neurosurgery

Mountain View, Calif. —Nov. 28, 2018—SanBio, Inc., a scientific leader in regenerative medicine for neurological disorders, today announced the publication of the two year follow up results of its phase 1/2a clinical trial in chronic stroke patients in the peer-reviewed Journal of Neurosurgery, published by the American Association of Neurological Surgeons. The paper, titled “Two-year safety and clinical outcomes in chronic ischemic stroke patients after implantation of modified bone marrow-derived mesenchymal stem cells (SB623): a phase 1/2a study,” further evaluates the safety and durability of clinical outcomes following intracerebral stereotactic implantation of its SB623 stem cell treatment. These data showed that patients living with motor impairments six months to five years following their stroke had statistically significant improvements in multiple measures of neurological function. No patients withdrew from the study and there were no dose-limiting toxicities or deaths. Measures of efficacy reached a plateau by 12 months with no decline thereafter.

Based on the encouraging data of this Phase 1/2a clinical trial, SanBio and its co-development partner Sunovion Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., in the United States and Canada, initiated a randomized, double-blind, controlled phase 2b (ACTIsSIMA) study. This study has now completed enrollment and expects data to be available by July 2019.

About SanBio, Inc. (SanBio)

SanBio is a regenerative medicine company headquartered in Tokyo and Mountain View, California, with cell-based products in various stages of research, development and clinical trials. Its proprietary cell-based product, SB623, is currently in a Phase 2b clinical trial for treatment of chronic motor impairments resulting from stroke. SanBio also began a Phase 2 clinical trial for treatment of motor impairment resulting from traumatic brain injury in late 2015. More information about SanBio, Inc. is available at <http://sanbio.com>.

#

For more information, contact:

SanBio Co., Ltd.
Management Administration
+81-3-6264-3481